Aviva’s Eli Lilly LLY Stock Holding History

Aviva’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$862M	Buy	718,261 +5,680	+0.8%	+$5.8M	1.27%	14
2026 Q1	$655M	Buy	712,581 +18,252	+3%	+$18.5M	1.1%	12
2025 Q4	$746M	Buy	694,329 +11,341	+2%	+$10.8M	1.26%	11
2025 Q3	$521M	Buy	682,988 +60,781	+10%	+$45.2M	0.95%	13
2025 Q2	$485M	Buy	622,207 +49,352	+9%	+$38.4M	1%	13
2025 Q1	$473M	Buy	572,855 +78,744	+16%	+$65.5M	1.14%	13
2024 Q4	$381M	Sell	494,111 -18,921	-4%	-$15.7M	0.99%	13
2024 Q3	$455M	Buy	513,032 +13,955	+3%	+$12.5M	1.18%	11
2024 Q2	$452M	Buy	499,077 +91,541	+22%	+$73.2M	1.25%	11
2024 Q1	$317M	Buy	407,536 +13,812	+4%	+$9.83M	1.04%	13
2023 Q4	$230M	Buy	393,724 +14,720	+4%	+$8.59M	0.82%	16
2023 Q3	$204M	Sell	379,004 -5,921	-2%	-$3.05M	0.86%	15
2023 Q2	$181M	Buy	384,925 +150,873	+64%	+$63.3M	0.74%	22
2023 Q1	$80.4M	Sell	234,052 -58,247	-20%	-$19.6M	0.36%	42
2022 Q4	$107M	Buy	292,299 +48,649	+20%	+$17.2M	0.53%	25
2022 Q3	$78.8M	Buy	243,650 +3,513	+1%	+$1.11M	0.45%	31
2022 Q2	$77.9M	Buy	240,137 +9,590	+4%	+$2.88M	0.41%	35
2022 Q1	$66M	Sell	230,547 -47,063	-17%	-$12.1M	0.33%	51
2021 Q4	$76.7M	Sell	277,610 -1,361	-0.5%	-$345K	0.32%	60
2021 Q3	$64.5M	Sell	278,971 -11,252	-4%	-$2.78M	0.29%	81
2021 Q2	$66.6M	Sell	290,223 -7,626	-3%	-$1.53M	0.29%	82
2021 Q1	$55.6M	Buy	297,849 +14,640	+5%	+$2.86M	0.27%	85
2020 Q4	$47.8M	Sell	283,209 -13,317	-4%	-$1.99M	0.25%	88
2020 Q3	$43.9M	Sell	296,526 -11,583	-4%	-$1.79M	0.26%	85
2020 Q2	$50.6M	Sell	308,109 -8,345	-3%	-$1.28M	0.32%	78
2020 Q1	$43.9M	Buy	316,454 +3,392	+1%	+$466K	0.32%	69
2019 Q4	$41.1M	Sell	313,062 -13,813	-4%	-$1.6M	0.25%	89
2019 Q3	$36.6M	Buy	326,875 +7,045	+2%	+$784K	0.25%	91
2019 Q2	$35.4M	Sell	319,830 -14,241	-4%	-$1.68M	0.24%	91
2019 Q1	$43.3M	Sell	334,071 -22,233	-6%	-$2.7M	0.29%	84
2018 Q4	$41.2M	Sell	356,304 -106,030	-23%	-$11.8M	0.31%	83
2018 Q3	$49.6M	Sell	462,334 -27,092	-6%	-$2.71M	0.27%	94
2018 Q2	$41.8M	Sell	489,426 -7,797	-2%	-$640K	0.25%	99
2018 Q1	$38.5M	Sell	497,223 -46,460	-9%	-$3.74M	0.24%	102
2017 Q4	$45.9M	Sell	543,683 -77,727	-13%	-$6.61M	0.26%	97
2017 Q3	$53.1M	Buy	621,410 +5,230	+0.8%	+$429K	0.29%	86
2017 Q2	$50.7M	Sell	616,180 -98,603	-14%	-$8.04M	0.28%	84
2017 Q1	$60.1M	Sell	714,783 -35,923	-5%	-$2.88M	0.34%	66
2016 Q4	$55.2M	Buy	750,706 +39,910	+6%	+$2.97M	0.33%	66
2016 Q3	$57M	Buy	710,796 +15,734	+2%	+$1.26M	0.36%	62
2016 Q2	$54.7M	Buy	695,062 +64,948	+10%	+$4.89M	0.38%	58
2016 Q1	$45.4M	Sell	630,114 -4,921	-0.8%	-$372K	0.34%	61
2015 Q4	$53.5M	Buy	635,035 +6,759	+1%	+$561K	0.41%	58
2015 Q3	$52.6M	Sell	628,276 -89,869	-13%	-$7.59M	0.44%	51
2015 Q2	$60M	Sell	718,145 -40,811	-5%	-$3.11M	0.42%	57
2015 Q1	$55.1M	Buy	758,956 +78,155	+11%	+$5.56M	0.38%	60
2014 Q4	$47M	Buy	680,801 +9,224	+1%	+$623K	0.36%	64
2014 Q3	$43.6M	Sell	671,577 -9,403	-1%	-$595K	0.34%	64
2014 Q2	$42.3M	Buy	680,980 +47,033	+7%	+$2.81M	0.32%	72
2014 Q1	$37.3M	Sell	633,947 -30,265	-5%	-$1.69M	0.3%	80
2013 Q4	$33.9M	Buy	664,212 +82,249	+14%	+$4.12M	0.28%	84
2013 Q3	$29.3M	Buy	581,963 +64,872	+13%	+$3.4M	0.26%	94
2013 Q2	$25.4M	Buy	+517,091	New	+$28.1M	0.26%	103

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aviva's LLY Position: Q2 2026 in Review

Aviva increased its Eli Lilly (LLY) stake by 0.8% in Q2 2026, buying an estimated $5.8M and bringing the position to 718,261 shares worth $862M. The position accounts for 1.27% of the portfolio, ranked #14.

Aviva first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 4,593 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Aviva held 718,261 shares of Eli Lilly worth $862M as of Q2 2026.
Aviva bought 5,680 Eli Lilly shares in Q2 2026, an estimated $5.8M.
Eli Lilly made up 1.27% of Aviva's portfolio in Q2 2026, its #14 holding.
Aviva first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
4,593 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.